Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

• Conditions: ALS

• Registration Number: NCT06743776
• Lead Sponsor: Mayo Clinic

Brief Summary

The purpose of this Expanded Access Program is to provide MN-166 (ibudilast) to ALS patients who are not eligible for an enrolling ALS clinical trial. This Expanded Access Program will assess if MN-166 can help people with ALS in slowing down the progression of the disease.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-11-20
• Study First Submitted QC: 2024-12-16
• Study First Posted: 2024-12-20
• Status Verified: 2025-01
• Last Update Submitted: 2025-10-08
• Last Update Posted: 2025-10-10

Recruitment & Eligibility

• Status: AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (4)

Semmes Murphey Foundation; 🇺🇸 Memphis, Tennessee, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Hospital for Special Care; 🇺🇸 New Britain, Connecticut, United States

Duke University; 🇺🇸 Durham, North Carolina, United States